--- title: "Cosmos Health (COSM) news: convertible notes and buyback" url: "https://aibio.space/companies/cosmos-health/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "COSM convertible notes and buyback news: Cosmos Health signs note facility of up to $300 million for Ethereum treasury. Cosmos Health Inc." --- COSM Cosmos Health Inc. NASDAQ · Greece # Cosmos Health (COSM) news COSM convertible notes and buyback news Company Updates · 2026-10-19 ## [Cosmos Health expects fourth-quarter U.S. revenue of about $15 million](https://aibio.space/news/cosmos-health-expects-fourth-quarter-u-s-revenue-about-15-million/) Cosmos Health said active U.S. subscriptions reached 8,940 as of October 19, 2026. It expects fourth-quarter U.S. revenue of approximately $15 million and gross profit of approximately $10.5 million. The figures are preliminary and unaudited. ## Latest Cosmos Health news 1. 2026-10-07 Company Updates [Cosmos Health reports preliminary nine-month revenue of $54.3 million](https://aibio.space/news/cosmos-health-reports-preliminary-nine-month-revenue-54-3-million/) Cosmos Health said preliminary revenue for the nine months ended September 30, 2026 was approximately $54.3 million, up 19%. The company reaffirmed its outlook for full-year 2026 revenue of more than $90 million. 2. 2026-08-19 Company Updates [Cosmos Health reports second-quarter 2026 revenue of $18.99 million](https://aibio.space/news/cosmos-health-reports-second-quarter-2026-revenue-18-99-million/) Revenue rose 28.8% and total liabilities fell 13.3% from year-end 2025, the company said. 3. 2026-06-30 Company Updates [Cosmos Health authorizes share repurchase of up to $5 million](https://aibio.space/news/cosmos-health-authorizes-share-repurchase-up-5-million/) The program expires December 31, 2026 and may be renewed at the company's discretion. 4. 2026-05-21 Company Updates [Cosmos Health reports first-quarter 2026 revenue of $17.93 million](https://aibio.space/news/cosmos-health-reports-first-quarter-2026-revenue-17-93-million/) Revenue rose 30.7% and total liabilities fell 9.6% in the quarter, and the company said its momentum continued into the second quarter. 5. 2026-04-15 Company Updates [Cosmos Health reports 2025 revenue of $65.3 million, up 20%](https://aibio.space/news/cosmos-health-reports-2025-revenue-65-3-million-up-20-percent/) Gross profit rose 83% to $7.90 million, and cash reached $3.46 million at December 31, 2025. 6. 2025-08-15 Distress [Cosmos Health files late notice for its June 30, 2025 quarterly report](https://aibio.space/news/cosmos-health-files-late-notice-june-30-2025-quarterly-report/) Cosmos Health said it could not finish its June 30, 2025 Form 10-Q on time, blaming delays in obtaining and compiling information, including its XBRL filing. It does not expect a significant change in results from a year earlier. 7. 2025-08-06 Financings [Cosmos Health signs note facility of up to $300 million for Ethereum treasury](https://aibio.space/news/cosmos-health-signs-note-facility-up-300-million-ethereum-treasury/) Cosmos Health agreed to issue up to $300 million of senior secured convertible promissory notes, with at least 72.5% of each tranche's net proceeds going to an Ethereum reserve. Curvature Securities, LLC was the sole placement agent, and the release gives no note terms or investor name. 8. 2025-05-07 Listings [Cosmos Health gets second 180-day Nasdaq period to lift stock above $1.00](https://aibio.space/news/cosmos-health-gets-second-180-day-nasdaq-period-lift-stock-above-1-00/) Nasdaq gave the company until November 3, 2025 to lift its bid above $1.00 for 10 straight business days. The first 180-day period expired on May 5, 2025, and the release gives no plan beyond the CEO's stated confidence. ## Cosmos Health at a glance - **Ticker**: COSM - **Listing**: NASDAQ - **Country**: Greece - **Cash, Jun 30, 2026**: $1.8 million ### Related companies - [Lavipharm SA](https://aibio.space/companies/lavipharm/) ATHEX: LAVI ### Also on NASDAQ - [Iambic Therapeutics](https://aibio.space/companies/iambic-therapeutics/) IAM - [aTyr Pharma](https://aibio.space/companies/atyr-pharma/) ATYR - [Precigen](https://aibio.space/companies/precigen/) PGEN - [Voyager Therapeutics](https://aibio.space/companies/voyager-therapeutics/) VYGR - [Research Alliance Corp III](https://aibio.space/companies/research-alliance-iii/) RACC - [RadNet](https://aibio.space/companies/radnet/) RDNT ## What Cosmos Health does Cosmos Health Inc. is a diversified, vertically integrated global healthcare group incorporated in Nevada in 2009. It owns proprietary pharmaceutical and nutraceutical brands, makes and distributes generics and healthcare products, conducts research and development on innovative medicines and drug repurposing, and operates a telehealth platform. Its markets include generic medicines, nutraceuticals, biocides, medical devices, novel oncology drugs, drug repurposing and telehealth services. Key proprietary brands named in the text are Sky Premium Life, Mediterranation and C-Sept and C-Scrub. Its growth strategy covers high-margin brands, generic pharmaceuticals, contract manufacturing and contract development and manufacturing, a global distribution network that includes the UAE and other GCC countries and Eastern Europe, and a corporate reorganization to reduce costs. Innovation programs named in the text include the CCX0722 obesity and weight management pill, CCDL24 for gastrointestinal disorders, and treatments for CNS, prostate, ovarian and colorectal cancers. The company also acquired Cloudscreen, an AI-driven drug repurposing platform. | Product or program | What it is | Stage | |---|---|---| | CCX0722 | Obesity and weight management pill | | | CCDL24 | Innovative treatment for gastrointestinal disorders | | | Cloudscreen | AI-driven drug repurposing platform addressing several treatment areas | recently acquired | | Sky Premium Life | Proprietary branded product line expanding into new fast growing regions | launches into new regions | Summarised from the company's [10-K filed Apr 15, 2026](https://www.sec.gov/Archives/edgar/data/1474167/000147793226002278/cosm_10k.htm). ## Cosmos Health annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$65.3 million](https://www.sec.gov/Archives/edgar/data/1474167/000147793226002278/) | [$54.4 million](https://www.sec.gov/Archives/edgar/data/1474167/000147793226002278/) | | Research and development | [$519,363](https://www.sec.gov/Archives/edgar/data/1474167/000147793226002278/) | [$533,293](https://www.sec.gov/Archives/edgar/data/1474167/000147793226002278/) | | Net income (loss) | [-$19.1 million](https://www.sec.gov/Archives/edgar/data/1474167/000147793226002278/) | [-$16.2 million](https://www.sec.gov/Archives/edgar/data/1474167/000147793226002278/) | | Cash from operations | [-$8.4 million](https://www.sec.gov/Archives/edgar/data/1474167/000147793226002278/) | [-$7.7 million](https://www.sec.gov/Archives/edgar/data/1474167/000147793226002278/) | | Cash and equivalents | [$715,674](https://www.sec.gov/Archives/edgar/data/1474167/000147793226005146/) | [$315,105](https://www.sec.gov/Archives/edgar/data/1474167/000147793226002278/) | | Short-term investments | [$46,158](https://www.sec.gov/Archives/edgar/data/1474167/000147793226005146/) | [$21,148](https://www.sec.gov/Archives/edgar/data/1474167/000147793226002278/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $1.8 million, plus short-term investments of $37,464, $1.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Cosmos Health Has Cosmos Health sold convertible notes? Our latest story on this, dated Aug 6, 2025: "Cosmos Health signs note facility of up to $300 million for Ethereum treasury". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cosmos-health-signs-note-facility-up-300-million-ethereum-treasury/). Does Cosmos Health have a share buyback? Our latest story on this, dated Jun 30, 2026: "Cosmos Health authorizes share repurchase of up to $5 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cosmos-health-authorizes-share-repurchase-up-5-million/). What is the ticker symbol of Cosmos Health? Cosmos Health Inc. trades under the ticker COSM on NASDAQ. Where is Cosmos Health listed? Cosmos Health Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:V67A; LS:A3DZZN; LSX:A3DZZN. What is the SEC CIK of Cosmos Health? The SEC Central Index Key (CIK) for Cosmos Health Inc. is 1474167. Its filings are on SEC EDGAR. How many shares does Cosmos Health have outstanding? 100,633,773 shares as of 2026-08-18, per the cover page of its 10-Q filed 2026-08-18. Which country or territory is Cosmos Health listed under? Our directory records Cosmos Health Inc. under Greece. What does Cosmos Health do? Our directory classifies Cosmos Health Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Cosmos Health? The ISIN recorded for Cosmos Health Inc. is US2214133058. Does aibio.space cover Cosmos Health? aibio.space lists Cosmos Health Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Cosmos Health incorporated? SEC records list its state or country of incorporation as NV. What does Cosmos Health develop? Cosmos Health Inc. is a diversified, vertically integrated global healthcare group incorporated in Nevada in 2009. It owns proprietary pharmaceutical and nutraceutical brands, makes and distributes generics and healthcare products, conducts research and development on innovative medicines and drug repurposing, and operates a telehealth platform. What is CCX0722 from Cosmos Health? CCX0722: Obesity and weight management pill Stage: not stated. What is CCDL24 from Cosmos Health? CCDL24: Innovative treatment for gastrointestinal disorders Stage: not stated. What was Cosmos Health's revenue last year? $65.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: Cosmos Health Members talk about Cosmos Health (COSM). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Cosmos Health, newest first. Each line links the filing it comes from. 1. 2026-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793226005084/cosm_nt10q.htm) 2. 2026-07-06 Financings Announced a share repurchase program. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793226004192/cosm_ex991.htm) 3. 2026-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793226003236/cosm_nt10q.htm) 4. 2026-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793226001897/cosm_nt10k.htm) 5. 2025-12-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793225009040/cosm_8k.htm) 6. 2025-11-07 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793225007981/cosm_s3.htm) 7. 2025-10-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793225007629/cosm_ex991.htm) 8. 2025-10-01 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793225007274/cosm_8k.htm) 9. 2025-08-22 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793225006195/cosm_def14a.htm) 10. 2025-08-18 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793225005997/cosm_10q.htm) 11. 2025-08-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793225005955/cosm_nt10q.htm) 12. 2025-08-12 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793225005683/cosm_pre14a.htm) 13. 2025-08-06 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793225005501/cosm_ex991.htm) 14. 2025-05-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793225003402/cosm_ex991.htm) 15. 2025-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793225002240/cosm_nt10k.htm) 16. 2024-12-18 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793224008191/cosm_s1.htm) 17. 2024-11-21 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793224007534/cosm_8k.htm) 18. 2024-11-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1474167/000147793224007041/cosm_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:COSM on TradingView](https://www.tradingview.com/symbols/NASDAQ-COSM/). ## SEC filings and registration - **SEC name**: Cosmos Health Inc. - **CIK**: 1474167 - **Industry (SIC)**: Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122) - **US tickers**: COSM (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 5 AGIOU GEORGIOU, PILEA, THESSALONIKI, Greece, 55438 - **Phone**: 312-536-3102 - **Shares outstanding**: 100,633,773 as of 2026-08-18 (10-Q filed 2026-08-18) - **Former names**: Cosmos Holdings Inc.; PRIME ESTATES & DEVELOPMENTS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1474167/000147793226006396/cosm_8k.htm) filed 2026-10-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1474167/000147793226006158/cosm_8k.htm) filed 2026-10-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1474167/000147793226005195/cosm_8k.htm) filed 2026-08-20 - [10-Q](https://www.sec.gov/Archives/edgar/data/1474167/000147793226005146/cosm_10q.htm) filed 2026-08-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1474167/000147793226004357/cosm_8k.htm) filed 2026-07-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1474167/000147793226004192/cosm_8k.htm) filed 2026-07-06 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1474167/000147793226003588/cosm_def14a.htm) filed 2026-06-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1474167/000147793226003403/cosm_8k.htm) filed 2026-05-22 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001474167), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Cosmos Health Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker COSM, recorded under Greece. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Cosmos Health Inc. - **Ticker**: COSM - **Listing**: NASDAQ - **Country or territory**: Greece - **Business scope**: Pharmaceuticals: Major - **ISIN**: US2214133058 - **Other listed symbols**: GETTEX:V67A; LS:A3DZZN; LSX:A3DZZN - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-COSM/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cosmos-health/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cosmos Health (COSM) news: convertible notes and buyback", 2026-10-31, https://aibio.space/companies/cosmos-health/